S-ClassAbout S-Class
A
ARGXAI Stock Diagnostic Report
Argenx upgraded at UBS; sees $20B peak sales in Vyvgart
UBS has upgraded its investment rating for argenx and significantly raised its target price, forecasting a maximum revenue potential of $20 billion for its flagship product.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$1046.0999755859375Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support826.45
Near-Term Resistance1058.69
02
FUNDAMENTALS
Financial & Fundamental Analysis
The peak sales of the flagship product Vyvgart are projected to reach $20 billion, significantly enhancing the company's long-term fundamentals and the potential for a valuation re-rating.
03
TECHNICAL VIEW
Technical Position & Response Criteria
The current stock price is near the 20-day high resistance level ($1058.69) and is in a bullish alignment; however, trading volume is below average, indicating a need for short-term volatility management.
Support826.45
Resistance1058.69
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
A report from UBS has upgraded its investment rating to Buy and raised the 12-month target price to $1,400, serving as a direct upward momentum.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-08-26)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.